Clinical trials: Prurigo Nodularis
Prurigo Nodularis
Study on the Treatment of Prurigo Nodularis With Stapokibart Injection
This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of Stapokibart Injection in the treatment of subjects with prurigo nodularis, and observe…
- Trial name
- NCT06424470
- Testing
- Stapokibart
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Keymed Biosciences Co.Ltd
Prurigo Nodularis, Nodularis Prurigo
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
The primary objectives of the study are to evaluate the effects of two doses of nalbuphine HCl ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in patients with prurigo nodularis and to…
- Conditions
- Prurigo Nodularis, Nodularis Prurigo, Prurigo, Pruritus
- Trial name
- NCT02174419
- Testing
- nalbuphine HCl ER tablets 90 mg BID, nalbuphine HCl ER tablets 180 mg BID
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 62 people
- Sponsor
- Trevi Therapeutics
Atopic Dermatitis, Psoriasis
Determinants of Chronic Inflammatory Skin Disease Trajectories
Although it is well known that the clinical expression and course of chronic inflammatory skin diseases are highly variable, there are insufficient epidemiological data on this, and the factors that determine the manifestation…
- Conditions
- Atopic Dermatitis, Psoriasis, Lichen Planus, Alopecia Areata
- Trial name
- NCT05928169
- Testing
- Topical and systemic drugs
- Where
- Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University Hospital Schleswig-Holstein
Atopic Dermatitis Eczema, Prurigo Nodularis
China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project
In order to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for type 2…
- Trial name
- CORNERSTONE (NCT05316805)
- Where
- China
- Volunteers
- 100,000 people
- Sponsor
- Peking University First Hospital
Prurigo Nodularis
Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (>=) 18 years of age with prurigo nodularis (PN) after a 16 week treatment period.
- Trial name
- NCT04501666
- Testing
- Nemolizumab 30 mg
- Where
- 100 sites in United States, Austria and 8 more
- Volunteers
- 286 people
- Sponsor
- Galderma R&D
Prurigo Nodularis
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study. The study consists of 3 periods: Screening period: 2 to 4 weeks. Treatment period: 24 weeks. Post-intervention follow-up period: 16 weeks.
- Trial name
- NCT06293053
- Testing
- Dupilumab
- Where
- 15 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sanofi
Lichen Simples Chronicus and Prurigo
Dapsone Prurigo Study
Principal aim of this study is to assess whether a combination of topical dapsone and clobetasol as a topical steroid is superior to clobetasol alone as treatment of prurigo nodularis or lichen simplex chronicus in a side to side…
- Trial name
- NCT01870050
- Testing
- Dapsone gel - verum
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cook County Health
Prurigo Nodularis
A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)
The purpose of this study is to demonstrate whether or not VPD-737, an NK1 receptor antagonist is safe and effective for treatment of prurigo nodularis versus placebo.
- Trial name
- NCT02196324
- Testing
- serlopitant
- Where
- 15 sites in Germany
- Volunteers
- 128 people
- Sponsor
- Vyne Therapeutics Inc.
Atopic Dermatitis
A Study to Assess Change in Disease Activity in Adolescents and Adults With Moderate to Severe Prurigo-type Atopic Dermatitis in Japan Who Are Treated With Oral Upadacitinib
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Around one-third of patients with AD have had at least 1 incidence of prurigo nodularis (PN), which is characterized by…
- Trial name
- ADMIRE (NCT05451316)
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- AbbVie
Nodular Prurigo
A Randomized, Double-blinded, Self-controlled Clinical Study of Intralesional Injection of 5-fluorouracil Plus Triamcinolone for the Treatment of Refractory Nodular Prurigo
Nodular pruritus is a chronic inflammatory skin disease manifested as individual or multiple highly keratotic nodules with severe itching.
- Trial name
- NCT06524323
- Testing
- 5-fluorouracil Injection, Triamcinolone Acetonide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Neurodermatitis
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)
Primary Objective: To demonstrate the efficacy of dupilumab on itch response in participants with prurigo nodularis (PN), inadequately controlled on topical prescription therapy or when those therapies are not advisable.
- Trial name
- NCT04202679
- Testing
- Dupilumab SAR231893, Moisturizers, Low to medium potent topical corticosteroids
- Where
- 57 sites in United States, Canada and 9 more
- Volunteers
- 160 people
- Sponsor
- Sanofi
Prurigo Nodularis
Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis
This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with Prurigo Nodularis.
- Trial name
- NCT06554509
- Testing
- SHR-1819 Injection
- Where
- China
- Volunteers
- 423 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Prurigo Nodularis
Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis
This study will evaluate the anti-pruritic effect of apremilast in patients with known PN.
- Trial name
- NCT03576287
- Testing
- Apremilast Oral Product
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Tanja Todberg, MD
Prurigo Nodularis, Pruritis
Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
Study of the efficacy, safety, tolerability, pharmacokinetics (PK), and immunogenicity of Vixarelimab (KPL-716) in subjects with prurigo nodularis (PN).
- Trial name
- NCT03816891
- Testing
- Vixarelimab
- Where
- 86 sites in United States, Australia and 11 more
- Volunteers
- 240 people
- Sponsor
- Genentech, Inc.
Prurigo Nodularis
A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis
The main objective of this study is to assess the long-term durability of response over a 24-week period following withdrawal of nemolizumab in participants with prurigo nodularis (PN) who previously responded to treatment in the…
- Trial name
- NCT05052983
- Testing
- Nemolizumab
- Where
- 14 sites in United States, Austria and 5 more
- Volunteers
- 34 people
- Sponsor
- Galderma R&D
Prurigo Nodularis, Itch
Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis
The goal is to evaluate the efficacy and safety of tofacitinib in treating refractory prurigo nodularis.The main questions it aims to answer are 1. whether tofacitinib is effective in treating prurigo nodularis in the longpterm.
- Trial name
- NCT06201715
- Testing
- Tofacitinib 5 MG
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
- Trial name
- NCT06516952
- Testing
- Povorcitinib
- Where
- 120 sites in United States, Argentina and 10 more
- Volunteers
- 349 people
- Sponsor
- Incyte Corporation
Prurigo Nodularis
A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine
Prurigo nodularis (PN) is a skin disease characterized by the presence of single to multiple symmetrically distributed, intensively itching nodules.
- Trial name
- CLEAR PN (NCT06087627)
- Testing
- Dupilumab SAR231893 (REGN668)
- Where
- 11 sites in Germany
- Volunteers
- 110 people
- Sponsor
- Sanofi
Prurigo Nodularis
A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (>=) 18 years of age with prurigo nodularis (PN) after a 16-week treatment period.
- Trial name
- NCT04501679
- Testing
- Nemolizumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 274 people
- Sponsor
- Galderma R&D
Prurigo Nodularis, Atopic Dermatitis
Transcriptomic Landscape of T Lymphocytes of Atopic Dermatitis, Atopic Prurigo Nodularis (of Besnier) and Non-atopic Prurigo Nodularis (of Hyde) Using Single Cell RNA-sequencing
Prurigo nodularis (PN) is a skin condition characterized by symmetrically distributed widespread, pruritic nodules that occurs in patients with chronic pruritus.
- Trial name
- PRURISEQ (NCT04681300)
- Testing
- Skin biopsy, Plastic surgery remnants
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris